Class / Patent application number | Description | Number of patent applications / Date published |
514150600 | Blood pressure affecting | 37 |
20110144026 | Method of Treating Low Blood Pressure - A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient. | 06-16-2011 |
20110190210 | PROMININ-1 PEPTIDE FRAGMENTS AND USES THEREOF - Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration. | 08-04-2011 |
20120115786 | AGENT FOR REDUCING RISK IN ONSET OF DISEASE ASCRIBABLE TO NON-DIPPER CIRCADIAN RHYTHM OF BLOOD PRESSURE - An agent for reducing risk in onset of diseases ascribable to non-dipping circadian profile of blood pressure is provided. This agent is capable of effectively lowering SBP from night to early morning in individuals with non-dipping circadian profile of blood pressure, in particular, normal individuals with normal SBP and DBP among them, and is thus capable of reducing risk in onset, particularly likely in the morning, of diseases caused by circadian variation of blood pressure. The agent is intended for administration to such subjects, and contains a hydrolysate or a concentrate thereof, containing Val-Pro-Pro and Ile-Pro-Pro and obtained by hydrolysis of animal milk protein. Reduction of risk may be expected in onset, particularly likely in the morning, of various diseases caused by risk of circadian variation of blood pressure, such as cerebral infarction, myocardial infarction,myocardialischemia, atherosclerosis, cardiac failure, cerebral stroke, coronary artery diseases, and peripheral vascular diseases. | 05-10-2012 |
20120196808 | Peptidic Vasopressin Receptor Agonists - The present application relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification. | 08-02-2012 |
20130116183 | PEPTIDES THAT INHIBIT ANGIOTENSIN CONVERTING ENZYME AND PEPTIDES WITH ANTIOXIDANT ACTIVITY PURIFIED FROM OVOTRANSFERRIN AND METHODS OF PRODUCING AND USING THE SAME - Described herein are methods of identifying and releasing bioactive peptides from ovotransferrin The method involves (a) contacting ovotransferrin with a reducing agent, a sonication step, a high pressure processing step, a heating step, a fermentation step, or any combination thereof, and (b) contacting the ovotransferrin after step (a) with a hydrolytic enzyme to produce bioactive peptides that exhibit angiotensin converting enzyme inhibitory activity or antioxidant activity when compared to the parent protein. The bioactive peptides may be added to foodstuffs, a medication, or to any potable, ingestible, or edible compositions. | 05-09-2013 |
20130210732 | AGENT FOR REDUCING RISK IN ONSET OF DISEASE ASCRIBABLE TO NON-DIPPER CIRCADIAN RHYTHM OF BLOOD PRESSURE - An agent for reducing risk in onset of diseases ascribable to non-dipping circadian profile of blood pressure is provided. This agent is capable of effectively lowering SBP from night to early morning in individuals with non-dipping circadian profile of blood pressure, in particular, normal individuals with normal SBP and DBP among them, and is thus capable of reducing risk in onset, particularly likely in the morning, of diseases caused by circadian variation of blood pressure. The agent is intended for administration to such subjects, and contains a hydrolysate or a concentrate thereof, containing Val-Pro-Pro and Ile-Pro-Pro and obtained by hydrolysis of animal milk protein. | 08-15-2013 |
20140155329 | Long-Acting Peptide Analogs - Long-acting agonistic analogs for CLR/RAMP receptors are provided that have an extended half-live in vivo. | 06-05-2014 |
20140315818 | METHODS AND PRODUCTS FOR TREATING PREECLAMPSIA AND MODULATING BLOOD PRESSURE - The invention relates to methods for altering biological parameters in a subject, such as reducing blood pressure in a subject, by displacing CLIP, using a CLIP inhibitor. The methods are useful for treating disorders such as preeclampsia and high blood pressure. | 10-23-2014 |
20160143983 | Leucine-Rich Peptide Compositions and Methods for Isolation - Disclosed are compositions comprising isolated peptides having a leucine content of from about 12 to about 40 weight percent. Also disclosed is a method for isolating leucine-rich peptides from protein sources such as bovine whey and methods of use for these peptides to provide beneficial effects in a human and/or animal such as increasing blood flow, decreasing blood pressure, increasing muscle mass, improving cognitive function, improving cardiovascular function, etc. | 05-26-2016 |
20170231979 | Methods and Compositions for Treating Vasomotor Symptoms | 08-17-2017 |
514150700 | Hypertension | 27 |
20100249034 | GFRALPHA3 AND ITS USES - The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, and immunoadhesions and antibodies to mammalian GFRα3, a novel α-subunit receptor of the GDNF (i.e. GFR) receptor family. It further relates to an assay for measuring activation of an α-subunit receptor by detecting tyrosine kinase receptor activation (i.e., autophosphorylation) or other activities related to ligand-induced α-subunit receptor homo-dimerization or homo-oligomerization. | 09-30-2010 |
20100286050 | METHOD OF PREVENTING PROGRESSION OF HYPERTENSION-INDUCED HEART FAILURE WITH PKC PEPTIDES - Methods are described for slowing or inhibiting the progression of heart failure in a mammalian subject suffering from chronic hypertension. The methods involve administering an εPKC, β1PKC, or βIIPKC peptide inhibitor, examples of which are provided. | 11-11-2010 |
20110039783 | PEPTIDE HAVING HYPOTENSIVE ACTIVITY - The present invention provides a novel peptide having a physiological activity. Because of having a hypotensive activity, this novel peptide is useful in treating a disease caused by hypertension. Also, an antibody to the novel peptide is provided. | 02-17-2011 |
20110053852 | USE OF PODOCAN PROTEIN IN TREATING CARDIOVASCULAR DISEASES - The present invention relates to compositions and methods for the treatment of intimal smooth muscle cell hyperplasia, restenosis following percutaneous coronary intervention, post-transplant vasculopathy, and pulmonary hypertension More particularly, the present invention relates to methods and pharmaceutical compositions for delivering podocan or podocan inhibitors to the arterial system of an animal, thus resulting in the down-regulation or up-regulation, respectively, of smooth muscle cell (SMC) functions such as SMC proliferation and migration Up-regulation of vascular smooth muscle cell proliferation and/or migration by podocan inhibition results in the treatment of vulnerable plaques, while down-regulation of vascular smooth muscle cell proliferation and/or migration via podocan delivery and/or up-regulation results in the treatment of intimal smooth muscle cell hyperplasia, restenosis following percutaneous coronary intervention, post-transplant or graft vasculopathy and pulmonary hypertension. | 03-03-2011 |
20110082084 | METHODS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE - The disclosure provides methods of preventing or treating heart failure in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 04-07-2011 |
20110166073 | ANTI-HYPERTENSIVE AGENT - The present invention provides an anti-hypertensive agent. The anti-hypertensive agent of the present invention contains, as an active ingredient, at least one peptide selected from the group consisting of peptides originally derived from globin proteolysate, each of which consists of one of the following amino acid sequences (1) to (6), or a globin proteolysate containing at least one of the peptides: (1) Val-Val-Tyr-Pro (SEQ ID: NO. 1); (2) Trp-Gly-Lys-Val-Asn (SEQ ID: NO. 2); (3) Trp-Gly-Lys-Val (SEQ ID: NO. 3); (4) Trp-Gly-Lys (SEQ ID: NO. 4); (5) Ala-Ala-Trp-Gly-Lys (SEQ ID: NO. 5); and (6) Phe-Glu-Ser (SEQ ID: NO. 6). | 07-07-2011 |
20120028902 | PEPTIDE AVAILABILITY - The present invention provides a process for producing a composition which is preferably a food, food intermediate, dietary supplement, feed or pet food, which comprises mixing together a peptide mixture, comprising a bioactive peptide, and a protein source having a protein quality (expressed as PER) of 2.4 or lower. The composition of the invention can be used to improve the bioavailability of bioactive peptides or used as a food, food intermediate, nutraceutical, dietary supplement, feed, or pet food. | 02-02-2012 |
20120220532 | METHOD FOR IDENTIFYING A SUBJECT AT RISK OF DEVELOPING HEART FAILURE BY DETERMINING THE LEVEL OF GALECTIN-3 OR THROMBOSPONDIN-2 - The present invention relates to a method for identifying a subject at risk of developing hypertensive end organ damage, such as and in particular heart failure, comprising: a) obtaining a biological sample of said subject; b) determining the level of at least one non-myocytal marker in said sample; c) comparing the level of said marker to a standard level; and d) determining whether the level of the marker is indicative of a risk for developing hypertensive end organ damage. The non-myocytical marker preferably is galectin-3 or thrombospondin-2. | 08-30-2012 |
20120283191 | Approach To Treat Intraocular Hypertension - The present invention relates to the use of antisecretory factors, such as antisecretory proteins, homologues, derivatives and/or fragments thereof having antisecretory activity, for the manufacture of a pharmaceutical composition for use in the treatment and/or prevention of intraocular hypertension. The invention thus relates to the use of pharmaceutical compositions comprising antisecretory factors in the treatment and/or prevention of intraocular hypertension, which is preferably characterized by hampered outflow of body fluid resulting in elevated pressure in the eye. The invention provides for a novel approach for treating and/or preventing such a condition turning the intraocular pressure to an acceptable level, optionally 21 mm Hg, or less. | 11-08-2012 |
20120329717 | NOVEL OMEGA CONOTOXIN PEPTIDES - This invention relates to an isolated, synthetic or recombinant peptide, wherein the peptide comprises the sequence: C K G K G A Xaa | 12-27-2012 |
20130035291 | OBTAINMENT OF BIOACTIVE PRODUCTS FROM COCOA HAVING INHIBITORY ACTIVITY AGAINST THE PEP ENZYME AND ANTIOXIDANT AND/OR ANTINEURODEGENERATIVE ACTIVITY - The present invention relates to the production of bioactive products from raw plant matter, namely cocoa extracts. The said products have one or more biopeptides with prolyl endopeptidase (PEP) enzyme inhibitory activity in vitro and/or antioxidant and/or antineurodegenerative capacity in vivo and can be used in dietetics and in the food and pharmaceutical industries. | 02-07-2013 |
20140011742 | Bioactive Peptides and Proteins Containing Bioactive Peptides, their Uses and Processes for Making the Same - A process for treating a protein before hydrolytic digestion, the process comprising exposing the protein to at least one cycle of microwave irradiation to produce a microwave treated protein containing one or more bioactive peptides. Further hydrolyzing the microwave treated protein to release at least one of the one or more bioactive peptides. A pharmaceutical composition, supplement and food product including the microwave treated protein or the one or more released bioactive peptides. | 01-09-2014 |
20140100166 | METHODS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE - The disclosure provides methods of preventing or treating heart failure in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 04-10-2014 |
20140296150 | Carrier-Linked Treprostinil Prodrugs - The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH). | 10-02-2014 |
20150018278 | PHOSPHORYLATION ON THE THR-248 AND/OR THR-250 RESIDUES OF TRANSCRIPTION FACTOR E2F4 AS A THERAPEUTIC TARGET IN PATHOLOGICAL PROCESSES ASSOCIATED WITH SOMATIC POLYPLOIDY - The object of the invention is based on inhibiting specific phosphorylation on Thr248 and/or Thr250 residues of human transcription factor E2F4 to inhibit somatic endoreduplication processes in postmitotic cells which may be associated with various pathological conditions. The invention covers all currently known methods for the specific inhibition of protein phosphorylation (including the expression of mutant forms of E2F4 without Thr residues phosphorylated by p38MAPK) or methods developed in the future that may be applied to Thr-248 and/or Thr-250 residues of human transcription factor E2F4. | 01-15-2015 |
20150111829 | USE OF MODIFIED VASOACTIVE INTESTINAL PEPTIDES IN THE TREATMENT OF HYPERTENSION - The present invention is based on the discovery that a VIP having a binding preference for VPAC2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, methods and compositions useful for the treatment and/or amelioration of hypertension are provided. | 04-23-2015 |
20150119332 | ISOFORM-SELECTIVE INHIBITORS AND ACTIVATORS OF PDE3 CYCLIC NUCLEOTIDE PHOSPHODIESTERASES - The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments. In particular, techniques are disclosed herein relating to the identification of a test compound that binds to an isolated polypeptide such as PDE3A2 and assaying the test compound for its ability to exhibit superior ability to interfere with binding of the isolated polypeptide when compared with at least a second isolated polypeptide such as of PDE3A1 and methods of treatment of cardiomyopathy, pulmonary hypertension involving the resulting test compound. | 04-30-2015 |
20150297670 | "Therapeutic Use of Peptide Inhibitors of NADPH Oxidase; Aerosolization as a Delivery Mechanism" - A method is provided for treatment of a condition mediated by Nox2 in a patient. The method comprises administering to the patient by inhalation a polypeptide as described herein, able to inhibit superoxide production by Nox2. Conditions treatable in this manner include, without limitation, one or more of: right ventricular hypertrophy; pulmonary hypertension; acute lung injury; obstructive sleep apnea; ischemia/reperfusion injury in the lung; pulmonary fibrosis; an obstructive lung disorder such as Chronic Obstructive Pulmonary Disease (COPD), asthma, cystic fibrosis and emphysema; and atherosclerosis | 10-22-2015 |
20160022772 | Cytokine Receptors as Targets for Hypertension Therapy and Methods of Use - The present disclosure provides methods of treating or ameliorating hypertension in a subject comprising administering a therapeutically effective amount of an IL-1 receptor antagonist. | 01-28-2016 |
20160106800 | METHODS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE - The disclosure provides methods of preventing or treating heart failure in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 04-21-2016 |
514160100 | Endothelin (e.g., ET-2, ET-3, etc.) or derivative affecting or utilizing | 2 |
20120083447 | Novel Therapeutic Treatments Using Centhaquin - Methods of treating hypertension, pain, and resuscitative hemorrhagic shock using an adrenergic agent, like centhaquin, are disclosed. The methods treat mammals, including humans. | 04-05-2012 |
20130210733 | METHODS OF TREATING LUNG DISEASE - Provided herein are methods of treating lung disease in a subject by administering to the subject a therapeutically effective amount of a mitotic kinesin inhibitor, optionally in combination with another therapy. | 08-15-2013 |
514160200 | Angiotensin converting enzyme (ACE) affecting | 5 |
20110263505 | Whey Protein Hydrolysate Containing Tryptophan Peptide Consisting of Alpha Lactalbumin and the Use Thereof - The invention relates to a whey protein hydrolysate, in particular a hydrolysate consisting of whey protein enriched with α-lactalbumin and α-lactalbumin, and the use thereof for producing pharmaceuticals, anti-hypertensive agents, food supplements, foodstuffs and animal feed, and to pharmaceuticals, anti-hypertensive agents, food supplements, foodstuffs and animal feed produced in this manner. The whey protein hydrolysate according to the invention, which has an ACE inhibiting and anti-hypertensive action, contains a physiologically active quantity of at least one peptide containing tryptophan, preferably at least one of the bio-active dipeptides Ile-Trp and Trp-Leu, and can be obtained by the extensive hydrolysis of whey protein isolates or of pure α-lactalbumin. | 10-27-2011 |
20110263506 | PEPTIDES HAVING AN ACE INHIBITING EFFECT - Use of the tripeptide ITP and salts thereof for the preparation of a functional food angiotensin-converting enzyme inhibitor. Also provided is the use of the combination of tripeptide MAP and the tripeptide ITP and salts thereof as an angiotensin-converting enzyme inhibitor in functional foods. | 10-27-2011 |
20130178424 | THERAPY FOR COMPLICATIONS OF DIABETES - A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ET | 07-11-2013 |
20140179609 | Whey protein hydrolysate containing tryptophan peptide consisting of alpha lactalbumin and the use thereof - In a method for producing a whey protein hydrolysate, a whey substrate, selected from the group consisting of whey, commercially available whey powder, whey protein isolate, whey protein preparations, and α-Lactalbumin obtained from whey, is enzymatically hydrolyzing at least with alcalase and trypsin as enzymes at a ratio of g enzymes/g whey substrate between 1:10 and 1:10,000 and at a temperature of between 30° C. and 70° C. within an incubation period of between 18 hours and 30 hours, until a hydrolysis degree of more than 50% of the protein of the whey substrate have a molecular weight of less than 4 kDa. The enzymes are inactivated by heating the enzymes to a temperature of 80° C. to 100° C. after the desired hydrolysis degree has been reached. | 06-26-2014 |
20150315236 | PEPTIDE - The invention provides a peptide comprising or consisting of FSY and variants thereof, particularly comprising or consisting of the sequence FTY, nucleic acids encoding said peptides and pharmaceutical and nutraceutical compositions comprising said peptide(s) and/or nucleic acids. Also provided is the use of such a peptide in therapy and in vitro methods of ACE-inhibition. | 11-05-2015 |